gefitinib

Known as: 4-(3Chloro-4-flurophenylamine)-7-methoxy-6(3-(4morpholinyl)quinazoline, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine, gefitinib [Chemical/Ingredient] 
An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly improved progression-free survival (PFS… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor (EGFR) gene… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
In human lung adenocarcinomas harboring EGFR mutations, a second-site point mutation that substitutes methionine for threonine at… (More)
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in specimens from patients with non-small-cell… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
CONTEXT More persons in the United States die from non-small cell lung cancer (NSCLC) than from breast, colorectal, and prostate… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a… (More)
Is this relevant?